Job Market Candidates

Sabra Zaraa, PharmD, MPH, PhC

Sabra is a fifth-year PhD candidate at The CHOICE Institute. She is a PharmD by training and worked as a clinical pharmacist at a public hospital in Tunisia. Working on research projects to update and improve hospital’s protocols sparked her interest in public health research which led her to pursue an MPH in Global Health leadership, management and policy at the University of Washington as a Fulbright scholar.

Her dissertation is focused on the health and economic burden of substandard and falsified medicines. She developed a model that can be used by countries to estimate the burden of having substandard and falsified medical products in their supply chain in terms of health outcomes and economic costs. Her model is currently being piloted by the Kenyan ministry of health.

While at UW, she was awarded the Stergachis Endowed Fellowship for International exchange and led a research project in Saudi Arabia to assess the medication utilization pattern among outpatients during the Hajj mass gathering, was a co-investigator in a pilot research grant awarded by the UW Population Health Initiative and received a Husky 100 nomination.

Sabra’s research interests include real-world data, strategy and study design, and mixed methods research to inform decision making as well as PROs and outcomes research, including development and validation of instruments. Some of her work has been featured in Vaccine, The Lancet Planetary Health and PLOS One and presented at the American Pharmacist’s Association and American Epilepsy Society meetings.

Curriculum Vitae.

Connect on LinkedIn. 



Yilin Chen, MPH, PhC

Yilin is a fourth-year PhD candidate at the CHOICE Institute, with more than 10 years of experience in population health research and over 6 years of experience in health economics. During her PhD training, she has worked on comparative effectiveness studies, economic modeling, costing studies, and discrete choice experiment to inform clinical, program, and policy decision making in collaboration with various stakeholders, such as the Institute for Clinical and Economic Review, Fred Hutchinson Cancer Center, MYDAWA (the first online pharmacy in Kenya), and the Department of Global Health at the University of Washington (UW).

Yilin has also led real-world evidence (RWE) and health economics and outcomes research (HEOR) projects, during her industry internships and work experience at Analysis Group. Yilin has a proven track record of delivering HEOR projects demonstrating the value of innovative medical technologies, including systemic assessment of disease burden, treatment patterns, evidence of effectiveness, budget impact, and cost-effectiveness.

Furthermore, Yilin has worked on several research initiatives, including designing a value-based formulary and modeling utilization and spending outcomes in partnership with Kaiser Permanente Washington Research Institute. Yilin’s presentation at the 2022 ISPOR conference was recognized as the Best Student Podium Presentation. In her dissertation, she is leveraging innovative methods to address the challenges associated with making approval and coverage decisions on tumor-agnostic therapies. She is a recipient of the 2022-2023 UW Magnuson Scholars award and received The Rockefeller-endowed China Medical Board Next Generation Fellowship during her MPH program at the UW.


Google Scholar: